ABSTRACT
Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that tumour response in this setting may predict long-term outcome of patients on adjuvant endocrine therapy, which argues for its broader application in treating hormone receptor-positive disease. From the research perspective, neoadjuvant endocrine therapy provides a unique opportunity for studies of endocrine responsiveness and the development of novel therapeutic agents.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant , Breast Neoplasms/metabolism , Female , Humans , Premenopause , Preoperative Care , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Treatment OutcomeABSTRACT
A method for monitoring the cross-sectional size of blood vessels rapidly is introduced. The method creates a one-dimensional (1-D) profile of a strip along the diameter of a vessel using magnetic resonance imaging (MRI). The strips can be much wider than pixels in a typical two-dimensional (2-D) image to increase the signal-to-noise ratio. A second strip perpendicular to the first is also imaged sequentially to allow the detection, estimation, and correction of errors in diameter measurements resulting from the strip inadvertently covering a chord, rather than a diameter. Diameter measurements derived from 1-D profiles agree with measurements derived from 2-D images. This method is nearly an order of magnitude faster than 2-D MRI and has the potential for real-time implementation. J. Magn. Reson. Imaging 1999;10:833-840.
